Scientists have decided to put a hold on the Swiss clinical trials of Ebola vaccine from NewLink and Merck, where some volunteers reported joint pains.
Global Alliance for Vaccines and Immunization (GAVI) and the Bill and Melinda Gates Foundation, said that they were set to begin procurement of the vaccine as soon as the World Health Organization (WHO) recommended a vaccine for use.
Ebola Virus Disease
Ebola is caused by a virus via direct contact with body fluids or infected blood. Scientists have identified five types of Ebola or Ebola hemorrhagic fever virus.
Advertisement
Ebola outbreak has been responsible for death of more than 6000 people in West Africa, and doses of Ebola vaccine may be needed in millions to help put an end to the current epidemic, and also prevent future outbreaks.
Source: Medindia
Ebola Fighters are Time's 2014 Person of the Year
Paying tribute to the courage and mercy of the medics who have treated Ebola patients, the Time magazine named them as its 'Person of the Year 2014'.
Advertisement
 Global Alliance for Vaccines and Immunization Will Purchase Millions of Ebola VaccineThe Global Alliance for Vaccines and Immunization has planned to purchase millions of Ebola vaccine doses as soon as a safe and effective one is found. | Advertisement
|
Ebola Vigilance Required Before Christmas: Red Cross
Vigilance against a possible spread of the Ebola virus was urged by the Red Cross on Thursday, as holiday travel picks up for the Christmas season in west Africa.
Advertisement
Recommended Reading
Latest Clinical Trials News
Amyotrophic lateral sclerosis patients' motor neurons responded robustly to Parkinson's drug ropinirole.
A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.
Scientists devise a fully integrated autonomous wearable ultrasonic-system-on-patch to sense deep tissue vital signs wirelessly even when the patient is on the move.